Annals of Medicine Research and Public Health (ISSN: 2995-5955) | Volume 5, Issue 2 | Review Article | Open Access
Loso Judijanto*
IPOSS Jakarta, Indonesia
*Correspondence to: Loso Judijanto
Fulltext PDFMetabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly understood as a multisystem cardiometabolic disorder whose clinical consequences extend from hepatic steatosis to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, hepatocellular carcinoma, cardiovascular disease, and chronic kidney disease. Tocotrienols, naturally occurring members of the vitamin E family and prominent bioactives in palm oil, have attracted interest because their biological actions intersect several mechanisms implicated in MASLD progression, including insulin resistance, lipotoxicity, oxidative stress, inflammatory signalling, mitochondrial dysfunction, and hepatocyte apoptosis. This qualitative literature review critically evaluates whether these mechanistic properties have translated into clinically meaningful disease modification. Human trials indicate that tocotrienol interventions can improve liver enzymes, indices of steatosis, insulin resistance, oxidative stress, inflammatory biomarkers, adipokines, and hepatocyte-apoptosis markers. However, current clinical evidence does not demonstrate histologically confirmed MASH resolution, reproducible fibrosis regression, prevention of cirrhosis, or reduction in liver-related and cardiovascular events. Interpretation is additionally complicated by differences between palm-derived tocotrienol-rich fractions, annatto-derived preparations, individual tocotrienol isomers, doses, and bioavailability. The review proposes an evidence hierarchy separating biochemical improvement from genuine disease modification and develops a translational roadmap incorporating source authentication, pharmacokinetic optimisation, phenotype-enriched recruitment, validated non-invasive fibrosis measurements, histological outcomes, and long-term cardiometabolic endpoints. Palm-derived tocotrienols should therefore be investigated as potential adjunctive metabolic interventions rather than regarded as established antifibrotic therapy.
Metabolic dysfunction-associated steatotic liver disease; MASLD; Metabolic dysfunction-associated steatohepatitis; MASH; Tocotrienols; Palm oil; Tocotrienol-rich fraction; Liver fibrosis; Insulin resistance; Cardiometabolic risk
Loso Judijanto. Beyond Steatosis: Palm-Derived Tocotrienols, Fibrosis, and Cardiometabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease—A Translational Review. Ann Med Res Pub Health. 2026;5(2):1-31.